By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Novo Nordisk A/S 

Novo Allé

Bagsvaerd    2880  Denmark
Phone: 45-4444-8888 Fax: 45-4449-0555


SEARCH JOBS

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

YEAR FOUNDED:

1922

LEADERSHIP:

Founders: August Krogh and Marie Krogh

CEO: Lars Rebien Sørensen

CFO: Jesper Brandgaard

CSO (Scientific): Mads Krosgsgaard Themsen

JOBS:

Please click here for Novo Nordisk job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW NOVO NORDISK:




Key Statistics


Email:
Ownership: Public

Web Site: Novo Nordisk A/S
Employees: 13395
Symbol: NVO
 



Industry
Big Pharma


Collaborations

CelTor Biosystems, Inc.  Research collaboration

Aradigm  Commercial agreement to develop AERx technology for the delivery of insulin, insulin analogues and other glucose-lowering agents for diabetes management.

Maxygen, Inc. 

Intergen Company 





Company News
Novo Nordisk A/S (NVO) - Share Repurchase Programme 5/24/2017 10:26:30 AM
Novo Nordisk A/S (NVO) Release: Early Response To Saxenda Resulted In Weight Maintenance And Additional Weight Loss Over 56 Week 5/17/2017 10:40:41 AM
Novelion (AEGR) CEO Steps Down From Novo Nordisk A/S (NVO) Board Due To NASH Conflict 5/16/2017 10:32:22 AM
Trading In Novo Nordisk A/S (NVO) Shares By Board Members, Executives And Associated Persons On 8 May 2017 5/9/2017 10:39:43 AM
Trading In Novo Nordisk A/S (NVO) Shares By Board Members, Executives And Associated Persons On 4 May 2017 5/5/2017 10:51:57 AM
Novo Nordisk A/S (NVO) Needs New Blood Despite Q1 Relief 5/5/2017 6:39:16 AM
Novo Nordisk A/S (NVO) Release: Heart Attacks, Strokes And Other Major Health Events Play Key Role In Driving Older Americans With Obesity To Address Their Weight 5/4/2017 12:15:44 PM
Novo Nordisk A/S (NVO) Increased Reported Operating Profit By 10% In The First Three Months Of 2017 5/3/2017 10:51:09 AM
Novo Nordisk A/S (NVO) Launches Xultophy 100/3.6 (Insulin Degludec And Liraglutide Injection) In The United States 5/3/2017 9:01:46 AM
Novo Nordisk A/S (NVO) - Share Repurchase Programme 5/2/2017 10:27:23 AM
12345678910...
//-->